169 related articles for article (PubMed ID: 15910680)
1. Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.
Fellström B; Zannad F; Schmieder R; Holdaas H; Jardine A; Rose H; Wilpshaar W;
Curr Control Trials Cardiovasc Med; 2005 May; 6(1):9. PubMed ID: 15910680
[TBL] [Abstract][Full Text] [Related]
2. Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study.
Solbu MD; Mjøen G; Mark PB; Holdaas H; Fellström B; Schmieder RE; Zannad F; Herrington WG; Jardine AG
Nephrol Dial Transplant; 2018 Jan; 33(1):102-112. PubMed ID: 27798199
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
4. FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics.
Zannad F; Kessler M; Grünfeld JP; Thuilliez C;
Fundam Clin Pharmacol; 2002 Oct; 16(5):353-60. PubMed ID: 12602460
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular disease in patients with renal disease: the role of statins.
Fellström B; Holdaas H; Jardine AG; Svensson MK; Gottlow M; Schmieder RE; Zannad F;
Curr Med Res Opin; 2009 Jan; 25(1):271-85. PubMed ID: 19210158
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
7. Randomised, open-label, multicentre trial comparing haemodialysis plus haemoperfusion versus haemodialysis alone in adult patients with end-stage renal disease (HD/HP vs HD): study protocol.
Lu W; Jiang GR;
BMJ Open; 2018 Jul; 8(7):e022169. PubMed ID: 30056391
[TBL] [Abstract][Full Text] [Related]
8. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
9. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
10. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial.
Jhund PS; McMurray JJ; Chaturvedi N; Brunel P; Desai AS; Finn PV; Haffner SM; Solomon SD; Weinrauch LA; Claggett BL; Pfeffer MA
Eur Heart J; 2015 Sep; 36(36):2463-9. PubMed ID: 26188211
[TBL] [Abstract][Full Text] [Related]
11. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Marrs JC; Saseen JJ
Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.
MacLeod A; Daly C; Khan I; Vale L; Campbell M; Wallace S; Cody J; Donaldson C; Grant A
Cochrane Database Syst Rev; 2001; (3):CD003234. PubMed ID: 11687058
[TBL] [Abstract][Full Text] [Related]
13. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Ray KK; Nicholls SJ; Ginsberg HD; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Cummings JL; Sweeney M; Schwartz GG
Am Heart J; 2019 Nov; 217():72-83. PubMed ID: 31520897
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.
Ridker PM; MacFadyen J; Cressman M; Glynn RJ
J Am Coll Cardiol; 2010 Mar; 55(12):1266-1273. PubMed ID: 20206456
[TBL] [Abstract][Full Text] [Related]
15. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.
Boaz M; Smetana S; Weinstein T; Matas Z; Gafter U; Iaina A; Knecht A; Weissgarten Y; Brunner D; Fainaru M; Green MS
Lancet; 2000 Oct; 356(9237):1213-8. PubMed ID: 11072938
[TBL] [Abstract][Full Text] [Related]
16. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
17. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
18. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.
Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; de Zeeuw D; Eckardt KU; McMurray JJV; Claggett B; Lewis EF; Pfeffer MA
Am J Kidney Dis; 2017 Oct; 70(4):522-531. PubMed ID: 28599901
[TBL] [Abstract][Full Text] [Related]
19. Determinants of cardiovascular risk in haemodialysis patients: post hoc analyses of the AURORA study.
Schneider A; Jardine AG; Schneider MP; Holdaas H; Holme I; Fellstroem BC; Zannad F; Schmieder RE;
Am J Nephrol; 2013; 37(2):144-51. PubMed ID: 23392089
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
